Introduction: Uveitis specialists and rheumatologists treat patients with anterior
INTRODUCTION
Anterior scleritis accounts for 99% of cases of scleritis, the vast majority of which are due to a noninfectious etiology. The incidence of scleritis is approximately 3.4 per 100,000 person-years [1] . Scleritis is associated with a systemic inflammatory disease in 30-40% of patients [1, 2] . In these patients, the treatment of ocular inflammation is partially dictated by treatment choices for the underlying systemic illness [3] . In patients without an underlying systemic illness, there is no clear consensus on optimal treatment regimen, and there are a wide array of potential therapeutic options [3] [4] [5] [6] [7] [8] .
Randomized controlled trials (RCTs) provide the highest level of evidence for treatment efficacy in the pharmacologic management of disease; however, scleritis has not been studied in this manner. There are several reasons for the lack of RCT data on this disease, including the cost considerations of carrying out such a trial and problems related to patient recruitment for a disease with low prevalence.
Formal treatment recommendations and guidelines are often derived from data from
RCTs as well as meta-analyses; in their absence, recommendations are often formed by consensus of expert opinion. We have previously shown that subspecialists differ significantly in their recommendations for the management of intermediate and posterior uveitis [9] [10] [11] . These differences are influenced by subspecialty training as well as issues concerning cost and prior authorization by insurance companies. We sought to examine the treatment preferences of uveitis specialists and rheumatologists in the management of idiopathic scleritis, with the specific aim of identifying factors which influence treatment choice.
METHODS
We constructed an email questionnaire that included a brief case vignette describing a patient with idiopathic scleritis involving one eye. There was an increased usage of biologic agents after adjustment for cost and prior authorization by uveitis specialists and by rheumatologists, but the change was only statistically significant for the rheumatologists (p\0.05). Local steroid injection was the first choice of two rheumatologists (intraocular steroid implant) and five uveitis specialists (periocular triamcinolone). Table 2 shows the second-choice treatment preference for each specialty before and after equalization for cost and prior authorization.
Biologics were the most common agents chosen by both specialties, with 51.8% of rheumatologists and 27.7% of ophthalmologists preferring this approach (difference between specialties was not significant after correction for the false discovery rate). There was an increased usage of biologics after equalization for cost and prior authorization by uveitis specialists and by rheumatologists, but the increase was not The majority of both types of specialists in our study chose a systemic immunosuppressive agent (DMARD) as their first therapeutic choice.
However, there was a strong preference for methotrexate use by rheumatologists, whereas it was more likely for uveitis specialists to choose mycophenolate mofetil. This difference appeared to persist after equalization for cost and prior authorization, indicating that specialty treatment paradigms rather than cost may be an important determinant in therapeutic choices. Since the most common systemic disease associated with scleritis is rheumatoid arthritis, and methotrexate is a preferred treatment for this, we believe that this thinking is reflected in the higher use of this medication by rheumatologists. While both agents may be used to treat anterior scleritis that is inadequately controlled with oral NSAIDS and prednisone [6] [7] [8] , this difference in usage has significant cost implications, as mycophenolate mofetil is approximately ten times more costly than methotrexate and has not been shown to be more efficacious [9, 12] . [4, 13, 14] . It is useful to understand that, in spite of this low risk, uveitis specialists may be willing to consider this option rather than using systemic immunosuppression.
A limitation of our study is that we presented only a single vignette for a patient with anterior scleritis, whereas there are often other factors that influence clinical decisions that we did not address. The low response rate of 8.6% of those surveyed could influence our results, since nonresponder bias may be due to survey recipients being less interested or familiar with treatment of scleritis. Furthermore, we were unable to track individuals who did not respond to our survey, which has the potential to lead to participation bias. In the United States, a large percentage of patients with scleritis are co-managed by rheumatologists and ophthalmologists who do not specialize in uveitis, and hence our results cannot be generalized to other countries.
Our study demonstrates that there may be significant differences in the therapeutic choices of specialists in the treatment of idiopathic scleritis. It is unlikely that direct comparisons among the therapeutic options for scleritis will be tested in a randomized controlled trial. All of the drugs preferred by both specialties have the potential for significant side effects and differ greatly in cost, without proof of superiority or even equivalence. In the absence of well-controlled studies, physicians must utilize information based on training, case series and reports, as well as personal experience and clinical judgment.
Since these decisions have meaningful impacts on both healthcare cost and disease management, further investigation is warranted.
CONCLUSIONS
Methotrexate was the agent most commonly chosen by both specialties, but uveitis specialists were more likely to choose mycophenolate in the treatment of anterior scleritis. Cost and the need for prior authorization were not a significant factor in these differences, suggesting that subspecialty training plays a role in these treatment decisions.
